{
  "extraction_metadata": {
    "timestamp": "2025-10-02T14:24:43.424330",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "total_countries": 8,
    "total_picos": 33,
    "temperature": 0.1
  },
  "picos_by_country": {
    "DE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Docetaxel",
          "Outcomes": ""
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Pemetrexed",
          "Outcomes": ""
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Nivolumab",
          "Outcomes": ""
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Pembrolizumab",
          "Outcomes": ""
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Atezolizumab",
          "Outcomes": ""
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Docetaxel in combination with nintedanib",
          "Outcomes": ""
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 negative tumours",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Docetaxel",
          "Outcomes": ""
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 negative tumours",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Pemetrexed",
          "Outcomes": ""
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 negative tumours and adenocarcinoma histology",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Docetaxel in combination with nintedanib",
          "Outcomes": ""
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 expressing tumours (PD-L1 expr â‰¥ 1% of tumour cells)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Pembrolizumab",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 10,
      "ContextTokens": 2237
    },
    "DK": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DK",
      "PICOs": [
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel monotherapy",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "standard of care therapy",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 10,
      "ContextTokens": 2509
    },
    "EN": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EN",
      "PICOs": [
        {
          "Population": "previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": ""
        },
        {
          "Population": "previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel plus nintedanib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 10,
      "ContextTokens": 2208
    },
    "FR": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "FR",
      "PICOs": [
        {
          "Population": "adult patients with advanced CBNPC, with KRAS G12C mutation, whose disease has progressed after at least one prior systemic treatment line",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "chemotherapy",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced CBNPC, with KRAS G12C mutation, whose disease has progressed after at least one prior systemic treatment line",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "immunotherapy",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 10,
      "ContextTokens": 2445
    },
    "IT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "IT",
      "PICOs": [],
      "ChunksUsed": 6,
      "ContextTokens": 1644
    },
    "PO": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PO",
      "PICOs": [
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sotorasib",
          "Outcomes": ""
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "adagrasib",
          "Outcomes": ""
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "chemotherapy (docetaxel or pemetrexed)",
          "Outcomes": ""
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel in combination with nintedanib",
          "Outcomes": ""
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "EGFR inhibitors in patients who have not received these medicines in the first line",
          "Outcomes": ""
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "osymertinib in patients previously treated with first or second generation EGFR blockers",
          "Outcomes": ""
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "ALK inhibitors if ALK gene rearrangement",
          "Outcomes": ""
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "immunity (nivolumab or atezolizumab)",
          "Outcomes": ""
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "palliative radiotherapy",
          "Outcomes": ""
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "symptomatic progression",
          "Outcomes": ""
        },
        {
          "Population": "patients with NDRP and the KRAS mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 10,
      "ContextTokens": 2218
    },
    "PT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PT",
      "PICOs": [
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel + nintedanib",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nivolumab",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 10,
      "ContextTokens": 2892
    },
    "SE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "SE",
      "PICOs": [
        {
          "Population": "patients with advanced non-small cell lung cancer (NSCLC) with the KRAS G12C mutation who have progressed after at least one prior line of systemic therapy and who have been treated with docetaxel",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced non-small cell lung cancer (NSCLC) with the KRAS G12C mutation who have progressed after at least one prior line of systemic therapy and who are not medically suitable for treatment with Docetaxel",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "best supportive care",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 10,
      "ContextTokens": 2296
    }
  }
}